AstraZeneca still waiting for FDA decision to resume U.S. trial-CEO


FRANKFURT, Sept 24 (Reuters) - AstraZeneca AZN.L is still waiting for the go-ahead from the U.S. drug regulator to restart the clinical trial of its COVID-19 vaccine hopeful in the United States, Chief Executive Pascal Soriot said on Thursday.

"We are awaiting to hear their decision," Soriot told a virtual World Economic Forum discussion.

(Reporting by Ludwig Burger Editing by Caroline Copley)

((; +49 (0)30 2201 33584 ;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.